Protective effect of composite earthworm powder against diabetic complications via increased fibrinolytic function and improvement of lipid metabolism in ZDF rats.
Thrombosis is the leading cause of mortality globally. It is not only a complication but also a risk factor for progression of diabetes. However, alternative oral therapies and prophylaxis with less adverse effect for thrombosis have not been well studied. In this study, composite powder containing earthworm (CEP) was used and its fibrinolytic activity was measured. CEP was found to have a high urokinase-type plasminogen activator like activity in an in vitro assay. It also had significantly shortened euglobulin clot lysis time (ECLT) at 4 and 24 h after ingestion in Sprague Dawley rats. Zucker Diabetic Fatty rats were used to assess the effect of CEP on diabetes and diabetic nephropathy. After 10 weeks of feeding, CEP significantly shortened ECLT and attenuated HbA1c, hepatic lipid accumulation, and urinary albumin excretion and improved glomerular mesangial matrix score. Therefore, CEP may have beneficial effects on diabetes and diabetic nephropathy.
a Miyato Yaso Institute Co. Ltd. Myoko , Japan.|b Graduate School of Science and Technology , Niigata , Japan.
Tomoko
T
Kawakami
b Graduate School of Science and Technology , Niigata , Japan.
Airi
A
Fujikawa
a Miyato Yaso Institute Co. Ltd. Myoko , Japan.
Yohei
Y
Ishiyama
c Department of Clinical Nutrition Science , Graduate School of Medical and Dental Sciences , Niigata , Japan.
Michihiro
M
Hosojima
d Department of Applied Molecular Medicine , Graduate School of Medical and Dental Sciences , Niigata , Japan.
Akihiko
A
Saito
e Center for Transdisciplinary Research , Niigata University , Niigata , Japan.
Masatoshi
M
Kubota
b Graduate School of Science and Technology , Niigata , Japan.|e Center for Transdisciplinary Research , Niigata University , Niigata , Japan.
Shinobu
S
Fujimura
b Graduate School of Science and Technology , Niigata , Japan.|e Center for Transdisciplinary Research , Niigata University , Niigata , Japan.
Motoni
M
Kadowaki
D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005285:Fermentation; D063285:Fibrin Clot Lysis Time; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D006706:Homeostasis / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D050356:Lipid Metabolism / Q000187:drug effects*; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications / Q000188:drug therapy; D009835:Oligochaeta / Q000737:chemistry*; D010960:Plasminogen Activators / Q000378:metabolism; D011208:Powders; D051381:Rats; D011924:Rats, Zucker; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy
D011208:Powders; D010960:Plasminogen Activators; D005341:Fibrinolysin; D005947:Glucose
diabetes; earthworm (Eisenia fetida); euglobulin clot lysis time; thrombosis; urokinase-type plasminogen activator